Ghimire, Bhagabati
Landy, Rebecca
Maroni, Roberta
Smith, Samuel G.
Debiram-Beecham, Irene
Sasieni, Peter D.
Fitzgerald, Rebecca C.
Rubin, Greg
Walter, Fiona M.
Waller, Jo
Attwood, Stephen
Parmar, Max
Delaney, Brendan
de Caestecker, John
Atkin, Wendy
Hackshaw, Allan
van Heyningen, Charles
Underwood, Tim
Stella, Alberto
Saxby, Charlotte
Lorincz, Attila
Turnbull, Naomi
Doorbar, Jamie
Mannion-Krase, Georgia
Kaimi, Irene
Kasanicki, Mary
Kelleher, Stephen
Stockley, Louise
Assari, Tracy
Kadyan, Sonakshi
Hollamby, Victoria
Edwards, Katie
MacDonald, Helen
Shaw, Viv
Leishman, Heather
Roper, Holly
McCloskey, Kate
Jung, Helen
Phillips, Alex
Masjak-Newman, Gosia
Fell, Kim
Collins, Helen
Zolle, Olga
McGlone, Pauline
Crabb, Tania
Merrin, Lauren
Cross, Martine
Jones, Alex
Simpson, Tom
Murray, Emma
Perugia, Andrew
Thompson, Marie
Dumbleton, Jen
Morar, Monique
Frowd, Nadia
Hardcastle, Antonia
Carmichael, Debbie
Maxton, Fiona
Farnworth, Frances
Baddeley, Elaine
Offman, Judith
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial
https://doi.org/10.1186/s12876-022-02630-1
Funding for this research was provided by:
Innovate UK (105857, 105857, 105857)
National Institutes of Health
Cancer Research UK (C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385, C14478/A21047, C8162/A16892, C8162/A25356, C7492/A17219, C8640/A23385)
Yorkshire Cancer Research
Medical Research Council (RG84369)
Article History
Received: 14 July 2022
Accepted: 20 December 2022
First Online: 10 January 2023
Declarations
:
: Ethics approval for the BEST3 trial was given by the East of England—Cambridge East Ethics Committee, reference 16/EE/0546. Written informed consent was obtained from all participants before any individual-level data was collected and any clinical procedure done. Trial registration was ISRCTN68382401. All methods used were performed in accordance with the Declaration of Helsinki.
: Not applicable.
: RCF is named on patents related to the Cytosponge and related assays that have been licenced to Medtronic by the Medical Research Council. RCF is a shareholder in Cyted Ltd, a company working on early detection technology. PDS reports consulting fees paid to his organisation from GRAIL Inc, outside of the submitted work and being on the advisory committee for NHS England on the use of the Cytosponge (unpaid). The remaining authors have no conflicts of interest to declare.